ArticleNature biotechnology2019
Worldwide CRISPR patent landscape shows strong geographical biases.
Article in Nature biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- CRISPR genome editing in food and feed crops: intellectual property challenges, global accessibility, and the Indian perspective.Transgenic research · 2026Review
- CRISPR-Cas9-mediated therapeutics: Current clinical trials and therapy approval landscape to treat human diseases.Molecular therapy. Nucleic acids · 2026Review
- To patent or not to patent: challenges and solutions to the patent ban on new genomic techniques plant in EU.GM crops & food · 2025Review
- Emerging, challenges and modernization path of gene privacy in China: from personal privacy to group privacy.Philosophy, ethics, and humanities in medicine : PEHM · 2025Review
- Genetically Modified Animal-Derived Products: From Regulations to Applications.Animals : an open access journal from MDPI · 2025Review
- The global patent landscape of emerging infectious disease monkeypox.BMC infectious diseases · 2024Article
- Making genome editing a success story in Africa.Nature biotechnology · 2024Article
- Article
- Genetically modified organisms: adapting regulatory frameworks for evolving genome editing technologies.Biological research · 2022Review
- Enabling Trade in Gene-Edited Produce in Asia and Australasia: The Developing Regulatory Landscape and Future Perspectives.Plants (Basel, Switzerland) · 2022Review
- Article
- Article
- The CRISPR revolution and its potential impact on global health security.Pathogens and global health · 2021Review
- Global Regulation of Genetically Modified Crops Amid the Gene Edited Crop Boom - A Review.Frontiers in plant science · 2021Review
- Governance Choices of Genome Editing Patents.Frontiers in political science · 2021Article
- The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape.Nature biotechnology · 2020Article
- From strict moral standards to ethical neutrality: a policy-guided shift in the patentability of human embryonic stem cells in China.Stem cell research & therapy · 2020Article
- Article
- Recent advances of genome editing and related technologies in China.Gene therapy · 2020Review
- The evolving landscape around genome editing in agriculture: Many countries have exempted or move to exempt forms of genome editing from GMO regulation of crop plants.EMBO reports · 2020Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
31164740What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.